Farallon Capital Opposes Terms of Merck’s Acceleron Takeover
(Bloomberg) -- Another top-10 holder in Acceleron Pharma Inc. has come out against its proposed $11.5 billion takeover by Merck & Co. Inc., arguing the sale price undervalues the company.
Farallon Capital Management, which owns a more than 4% stake in Acceleron, said in an emailed statement that it appreciated the value the management team has created and the strategic position it has achieved. But it said it doesn't support the terms of the sale.
“While we hold Merck in high regard, its offer of $180 per share does not recognize the value of the company's uniquely strategic position,” the firm said. “We believe Acceleron has a clear path to substantial value creation as a standalone company, and less strategic assets have recently been sold for far higher valuations.”
Acceleron fell 0.5% to $173.04 at 10:30 a.m. in New York trading Tuesday, giving the company a market value of about $10.6 billion.
Representatives for Acceleron and Merck weren't immediately available for comment.
Farallon's opposition is another blow to Acceleron's plans to sell itself.
Merck agreed to buy Acceleron in September and said it expects the deal to close by year end. But Merck needs a majority of a Acceleron's shareholders to tender their shares in order for the deal to proceed. The price values Acceleron at a 34% premium to where it traded at the end of August.
That's not good enough for several large investors that have expressed reservations about the deal. Darwin Global Management, which owns a 3.8% stake in the company, and Holocene Advisors, have said they won't tender their shares.
Another top holder, Avoro Capital Advisors, which owns about 7% of Acceleron, has been vocal in its opposition to the deal. It argued in a letter to shareholders last week that a sale at $180 a share is not needed at the time, especially at that price.
Avoro has argued that there are other avenues the company could pursue to raise capital, including remaining independent and monetizing royalties.
Behzad Aghazadeh, Avoro Capital managing partner, said if the current board is unwilling to forgo the Merck deal and pursue a standalone strategy, he would be willing to revamp the board and add directors with relevant experience.
Bristol-Myers Squibb Co., Acceleron's largest shareholder, plans to tender its shares in the deal, people familiar with the matter told Bloomberg News last month. Bristol-Myers owns a 11.5% stake in the company, according to data compiled by Bloomberg.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.